Al-Samkari H - Search Results

1

An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: the InHIBIT-Bleed study.

Al-Samkari H, Kasthuri RS, Parambil JG, Albitar HA, Almodallal YA, Vázquez C, Serra MM, Dupuis-Girod S, Wilsen CB, McWilliams JP, Fountain EH, Gossage JR, Weiss CR, Latif MA, Issachar A, Mei-Zahav M, Meek ME, Conrad M, Rodriguez-Lopez J, Kuter DJ, Iyer VN. Al-Samkari H, et al. Haematologica. 2021 Aug 1;106(8):2161-2169. doi: 10.3324/haematol.2020.261859. Haematologica. 2021. PMID: 32675221 Free PMC article.

2

The relative risk of bleeding after medical hospitalization: the medical inpatient thrombosis and hemorrhage study.

Gergi M, Wilkinson K, Koh I, Munger J, Al-Samkari H, Smith NL, Roetker NS, Plante TB, Cushman M, Repp AB, Holmes CE, Zakai NA. Gergi M, et al. J Thromb Haemost. 2023 Mar;21(3):513-521. doi: 10.1016/j.jtha.2022.11.023. Epub 2022 Dec 22. J Thromb Haemost. 2023. PMID: 36696219 Free PMC article.

3

The use of romiplostim in treating chemotherapy-induced thrombocytopenia in patients with solid tumors.

Al-Samkari H, Marshall AL, Goodarzi K, Kuter DJ. Al-Samkari H, et al. Haematologica. 2018 Apr;103(4):e169-e172. doi: 10.3324/haematol.2017.180166. Epub 2017 Dec 14. Haematologica. 2018. PMID: 29242295 Free PMC article. No abstract available.

4

Romiplostim for the management of perioperative thrombocytopenia.

Al-Samkari H, Marshall AL, Goodarzi K, Kuter DJ. Al-Samkari H, et al. Br J Haematol. 2018 Jul;182(1):106-113. doi: 10.1111/bjh.15280. Epub 2018 May 16. Br J Haematol. 2018. PMID: 29767837 Free article.

5

Hereditary hemorrhagic telangiectasia: diagnosis and management from the hematologist's perspective.

Kritharis A, Al-Samkari H, Kuter DJ. Kritharis A, et al. Haematologica. 2018 Sep;103(9):1433-1443. doi: 10.3324/haematol.2018.193003. Epub 2018 May 24. Haematologica. 2018. PMID: 29794143 Free PMC article. Review.

6

Relative potency of the thrombopoietin receptor agonists eltrombopag, avatrombopag and romiplostim in a patient with chronic immune thrombocytopenia.

Al-Samkari H, Kuter DJ. Al-Samkari H, et al. Br J Haematol. 2018 Oct;183(2):168. doi: 10.1111/bjh.15432. Epub 2018 Jul 5. Br J Haematol. 2018. PMID: 29978577 Free article. No abstract available.

7

An alternative intermittent eltrombopag dosing protocol for the treatment of chronic immune thrombocytopenia.

Al-Samkari H, Kuter DJ. Al-Samkari H, et al. Br J Clin Pharmacol. 2018 Nov;84(11):2673-2677. doi: 10.1111/bcp.13717. Epub 2018 Aug 13. Br J Clin Pharmacol. 2018. PMID: 30032487 Free PMC article.

8

Thrombopoietin level predicts response to treatment with eltrombopag and romiplostim in immune thrombocytopenia.

Al-Samkari H, Kuter DJ. Al-Samkari H, et al. Am J Hematol. 2018 Dec;93(12):1501-1508. doi: 10.1002/ajh.25275. Epub 2018 Sep 26. Am J Hematol. 2018. PMID: 30187942 Free article.

9

Systemic bevacizumab for the treatment of chronic bleeding in hereditary haemorrhagic telangiectasia.

Al-Samkari H, Kritharis A, Rodriguez-Lopez JM, Kuter DJ. Al-Samkari H, et al. J Intern Med. 2019 Feb;285(2):223-231. doi: 10.1111/joim.12832. Epub 2018 Oct 9. J Intern Med. 2019. PMID: 30191646 Free article.

10

Infections and vaccination in hereditary hemorrhagic telangiectasia: microbiological evidence-based considerations.

Al-Samkari H, Kritharis A, Kuter DJ. Al-Samkari H, et al. Haematologica. 2018 Oct;103(10):e492-e495. doi: 10.3324/haematol.2018.203968. Haematologica. 2018. PMID: 30270207 Free PMC article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

170 results

Search Page

Filters